RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has signed agreements with two European firms to get the company’s commercial-grade RCI-02 dermal injector prototypes manufactured and tested.
“The execution of these agreements covers what we believe to be the final stages needed to prepare RCI-02 for a market authorization application in the form of a CE Mark in Europe,” president and CEO, Lee Buckler, said in a statement.
“With our first functional prototypes scheduled for this summer, we continue to work toward having this device ready for a CE mark application and in the hands of a licensing and commercial partner next year,” he added.
“While we had originally hoped to receive some of our clinical data in February, we remain confident all three clinical data sets will be received and announced very shortly and all still before the end of the quarter,” Mr. Buckler said.
AMI is an Austrian manufacturer of medical technology based near the shores of Lake Constance, within easy reach of Germany and Switzerland. AMI develops, manufactures and distributes their medical products throughout the world.
Art of Technology, based in Zurich, is an independent contract developer specializing in the design, development and miniaturization of complex customer specific electronic devices and embedded systems for use in industrial, medical and space applications.
